210 related articles for article (PubMed ID: 15647762)
1. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
Liu R; Martuza RL; Rabkin SD
Gene Ther; 2005 Apr; 12(8):647-54. PubMed ID: 15647762
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
Liu R; Varghese S; Rabkin SD
Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus vectors for the treatment of human breast cancer.
Liu RB; Rabkin SD
Chin Med J (Engl); 2005 Feb; 118(4):307-12. PubMed ID: 15740669
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of HSV mass distribution in a rodent brain tumor model.
Schellingerhout D; Rainov NG; Breakefield XO; Weissleder R
Gene Ther; 2000 Oct; 7(19):1648-55. PubMed ID: 11083473
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector.
Rainov NG; Dobberstein KU; Heidecke V; Dorant U; Chase M; Kramm CM; Chiocca EA; Breakefield XO
Cancer Gene Ther; 1998; 5(3):158-62. PubMed ID: 9622099
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
9. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
10. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
12. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
13. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47Delta.
Prabhakar S; Messerli SM; Stemmer-Rachamimov AO; Liu TC; Rabkin S; Martuza R; Breakefield XO
Cancer Gene Ther; 2007 May; 14(5):460-7. PubMed ID: 17304235
[TBL] [Abstract][Full Text] [Related]
14. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic herpes simplex virus vectors for cancer virotherapy.
Varghese S; Rabkin SD
Cancer Gene Ther; 2002 Dec; 9(12):967-78. PubMed ID: 12522436
[TBL] [Abstract][Full Text] [Related]
16. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice.
Ebert O; Harbaran S; Shinozaki K; Woo SL
Cancer Gene Ther; 2005 Apr; 12(4):350-8. PubMed ID: 15565179
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
19. Selective delivery of herpes virus vectors to experimental brain tumors using RMP-7.
Barnett FH; Rainov NG; Ikeda K; Schuback DE; Elliott P; Kramm CM; Chase M; Qureshi NH; Harsh G; Chiocca EA; Breakefield XO
Cancer Gene Ther; 1999; 6(1):14-20. PubMed ID: 10078959
[TBL] [Abstract][Full Text] [Related]
20. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
